BP
MRNA icon

Ballentine Partners’s Moderna MRNA Stock Holding History

Ballentine Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$241K Buy
+3,444
New +$178K ﹤0.01% 916
2025
Q3 		– Sell
-8,226
Closed -$227K – 1050
2025
Q2 		$227K Buy
+8,226
New +$217K ﹤0.01% 824
2024
Q3 		– Sell
-4,564
Closed -$542K – 869
2024
Q2 		$542K Sell
4,564
-183
-4% -$23.2K 0.01% 391
2024
Q1 		$506K Buy
4,747
+2,641
+125% +$266K 0.01% 386
2023
Q4 		$209K Sell
2,106
-876
-29% -$73.7K ﹤0.01% 606
2023
Q3 		$308K Buy
2,982
+868
+41% +$96.8K 0.01% 439
2023
Q2 		$257K Sell
2,114
-646
-23% -$86.2K 0.01% 477
2023
Q1 		$424K Sell
2,760
-166
-6% -$27.4K 0.01% 329
2022
Q4 		$526K Buy
2,926
+414
+16% +$67.7K 0.02% 271
2022
Q3 		$297K Buy
2,512
+594
+31% +$90.1K 0.01% 342
2022
Q2 		$273K Buy
1,918
+100
+6% +$14.3K 0.01% 343
2022
Q1 		$314K Buy
1,818
+24
+1% +$4.04K 0.01% 344
2021
Q4 		$455K Sell
1,794
-1
-0.1% -$292 0.01% 291
2021
Q3 		$691K Buy
1,795
+186
+12% +$68.6K 0.02% 196
2021
Q2 		$378K Sell
1,609
-34
-2% -$6.08K 0.01% 281
2021
Q1 		$215K Buy
+1,643
New +$238K 0.01% 367

Other funds holding MRNA

DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
MIM
Morningstar Investment Management Chicago, Illinois $1.62B AUM 13.96% 1-Year Est. Return
LAI
Legal Advantage Investments Los Altos Hills, California $285M AUM 18.63% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Ballentine Partners's MRNA Position: Q2 2026 in Review

Ballentine Partners opened a new position in Moderna (MRNA) in Q2 2026: 3,444 shares worth $241K. The stake represents ﹤0.01% of the portfolio and ranks #916 among its holdings. This is a return to the name: Ballentine Partners previously reported a position in MRNA as recently as Q2 2025.

Ballentine Partners first reported a position in MRNA in Q1 2021 and has held it in 16 quarters since. The position peaked at $691K in Q3 2021. 131 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Ballentine Partners held 3,444 shares of Moderna worth $241K as of Q2 2026.
  • Moderna was a new Ballentine Partners position in Q2 2026.
  • Moderna made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #916 holding.
  • Ballentine Partners first reported a position in Moderna in Q1 2021 and has held it in 16 quarters since.
  • Ballentine Partners's Moderna position peaked at $691K in Q3 2021.
  • 131 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.